5-(2-chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine
ticlopidine hydrochloride
CAS: 53885-35-1
Molecular Formula: C14H14ClNS.ClH
5-(2-chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine - Names and Identifiers
| Name | ticlopidine hydrochloride |
| Synonyms | 4-c-32 ticlid 53-32c ticlodix panaldine ticlodone Ticlopidine HCL ticlopidine hydrochloride ticlodipine hydrochloride tiolopidine hydrochloride 5-(2-chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine 5-(o-chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridinium chloride |
| CAS | 53885-35-1 |
| EINECS | 258-837-4 |
| InChI | InChI=1/C14H14ClNS.ClH/c15-13-4-2-1-3-11(13)9-16-7-5-14-12(10-16)6-8-17-14;/h1-4,6,8H,5,7,9-10H2;1H |
5-(2-chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine - Physico-chemical Properties
| Molecular Formula | C14H14ClNS.ClH |
| Molar Mass | 300.25 |
| Density | 1.37 g/cm3 |
| Melting Point | 205°C |
| Boling Point | 367.3°C at 760 mmHg |
| Flash Point | 175.9°C |
| Water Solubility | Soluble to 100 mM in water and to 100 mM in DMSO. |
| Solubility | DMSO, water |
| Vapor Presure | 1.38E-05mmHg at 25°C |
| Appearance | White powder |
| Color | White |
| Maximum wavelength(λmax) | ['295nm(H2O)(lit.)'] |
| Merck | 14,9421 |
| pKa | 7.64(at 25℃) |
| Storage Condition | Inert atmosphere,Room Temperature |
| Use | This product is for scientific research only and shall not be used for other purposes. |
| In vitro study | Ticlopidine HCl is an antiplatelet agent in the thienopyridine family. Ticlopidine HCl inhibits platelet aggregation by blocking the ADP receptor to change the function of platelet membrane. This impedes the conformational change of glycoprotein IIb/IIIa, allowing platelets to bind to fibrinogen. Ticlopidine HCl inhibits platelet aggregation and prostaglandin synthesis from endogenous substrates by activating basal pge1-induced cyclase activity and blocking pge2-induced cyclase to increase platelet c-AMP levels. |
| In vivo study | Ticlopidine HCl inhibits platelet aggregation, with an IC50 of 2 μm in men. Oral administration of Ticlopidine HCl in rats leads to basal and prostaglandin E1(PGE1)-stimulated activation of adenylate cyclase by increasing the affinity of platelet membrane cyclase to PGE1, the enzyme activity induced by adenosine or sodium fluoride was not affected. |
5-(2-chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine - Risk and Safety
| Risk Codes | R22 - Harmful if swallowed R36/37/38 - Irritating to eyes, respiratory system and skin. |
| Safety Description | S36 - Wear suitable protective clothing. S37/39 - Wear suitable gloves and eye/face protection S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. |
| WGK Germany | 3 |
| RTECS | XJ9089100 |
| HS Code | 2934990002 |
| Toxicity | LD50 in mice (mg/kg/24 hrs): 55 i.v.; >300 orally (Castaigne) |
5-(2-chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine - Nature
Open Data Verified Data
white or yellowish crystalline powder, with special odor, bitter taste. Soluble in acetic acid, ethanol or water, soluble in 95% ethanol, methanol or chloroform, slightly soluble in n-butanol, insoluble in ether. Melting point 190 °c (ethanol).
Last Update：2024-01-02 23:10:35
5-(2-chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine - Preparation Method
Open Data Verified Data
The thiophene was dissolved in anhydrous ether, and a solution of butyl lithium ether was slowly added dropwise at 0 ° C., followed by stirring at room temperature. Ethylene oxide ether solution was then added dropwise and treated to give 2-Hydroxyethyl thiophene. It was dissolved in pyridine and p-Toluenesulfonyl chloride was added in portions below 5 °c and stirred at room temperature to work up the sulfonylated product. The sulfonylated product and O-chlorobenzylamine were dissolved in toluene and refluxed. The solid was filtered off and the filtrate was extracted with hydrochloric acid. The extract was concentrated and placed. The precipitate was washed with acetone. Then it is stirred with formaldehyde and water, reflux, the filtrate is alkalized with dilute sodium hydroxide, isopropyl ether extraction, after treatment, add a little concentrated hydrochloric acid and acetone, place, precipitate crystals, that is, ticlopidine hydrochloride.
Last Update：2022-01-01 09:23:40
5-(2-chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine - Standard
Authoritative Data Verified Data
This product is 5-[(2-chlorophenyl) methyl]-4,5,6, 7-tetrahydrothieno [3,2-c] pyridine hydrochloride. The content of C14H14C1NS • HC1 shall be between 98.0% and 102.0% calculated as dry.
Last Update：2024-01-02 23:10:35
5-(2-chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine - Trait
Authoritative Data Verified Data
- This product is white or off-white crystalline powder; Odorless, slightly salty.
- This product is dissolved in methanol or chloroform, slightly soluble in water, very slightly soluble in acetone; Soluble in glacial acetic acid.
Last Update：2022-01-01 15:35:50
5-(2-chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine - Use
Open Data Verified Data
It was developed and listed by French Sanofi company. It was approved by FDA for sale in the United States in 1997, and domestic ticlopidine was approved for production in 1997. Anti-platelet aggregation drugs, can inhibit ADP, collagen, thrombin, arachidonic acid and prostaglandin endoperoxide and other inducers caused by platelet aggregation, it can inhibit platelet aggregation induced by exogenous and endogenous ADP. For vascular surgery and extracorporeal circulation thrombosis, arterial occlusive vasculitis and arteriosclerosis obliterans. May reduce the incidence of vascular necrosis in stroke, myocardial infarction, or thromboembolic stroke.
Last Update：2022-01-01 09:23:40
5-(2-chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine - Differential diagnosis
Authoritative Data Verified Data
- take about 1 mg of this product, add formaldehyde sulfuric acid test solution in 1 ml, the liquid surface is purple red.
- take this product, add water to dissolve and dilute to make a solution containing about 0401 mg per 1 ml, and measure by UV-Vis spectrophotometry (general rule), there is maximum absorption at wavelengths of 267nm and 276nm.
- The infrared absorption spectrum of this product should be consistent with that of the control (Spectrum set 640).
- This product is chloride identification reaction (General 0301).
Last Update：2022-01-01 15:35:50
5-(2-chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine - Use
Open Data Verified Data
MICE (24h) LDso: 55mg/kg I. V.;>300mg/kg by mouth.
Last Update：2022-01-01 09:23:41
5-(2-chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine - Exam
Authoritative Data Verified Data
acidity
take 0.10g of this product, Add 10ml of water to dissolve, and measure according to law (General rule 0631). The pH value should be 3.0~4.5.
clarity of acidic solution
take 0.50g of this product, add 20ml of hydrochloric acid solution (1-0902) to dissolve, the solution should be clear; If it is turbid, compare with No. 1 turbidity standard solution (General rule first method), not more concentrated.
Related substances
take this product, add mobile phase to dissolve and dilute to make a solution containing about 0.3mg per lml, as a test solution, take an appropriate amount of precision, A solution containing 3ug per 1 ml was prepared as a control solution by quantitative dilution with mobile phase. According to the chromatographic conditions under the content determination item, 20 u1 of the test solution and the control solution are respectively injected into the liquid chromatograph, and the chromatogram is recorded to 2 times of the retention time of the main component peak. If there are impurity peaks in the chromatogram of the test solution, the sum of each impurity peak area shall not be greater than the main peak area of the control solution (1.0%).
residual solvent
take this product, precision weighing, add dimethyl sulfoxide to dissolve and dilute to make a solution containing about 40mg per 1 ml, as a test solution; Take toluene, precision weighing, A solution containing about 35.6ug per 1 ml was prepared by dissolving and diluting with dimethyl sulfoxide as a control solution. According to the residual solvent determination method (General 0861 third method), the column is 5% phenyl-95% methyl polysiloxane capillary column; Column temperature 50°C. 1-3 u1 of each of the test solution and the reference solution were accurately measured and injected into the gas chromatograph respectively, and the chromatograms were recorded. According to the external standard method to calculate the peak area, the residual amount of toluene should comply with the provisions.
loss on drying
take this product, dry to constant weight at 105°C, weight loss shall not exceed 0.5% (General rule 0831).
ignition residue
take l.Og of this product and check it according to law (General rule 0841). The residue left shall not exceed 0.1%.
Heavy metals
The residue left under the item of taking the ignition residue shall not contain more than 10 parts per million of heavy metal when examined by law (General Principles 0821, Law II).
Last Update：2022-01-01 15:35:51
5-(2-chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine - Content determination
Authoritative Data Verified Data
measured by high performance liquid chromatography (General 0512).
chromatographic conditions and system suitability test
silica gel bonded with octanoalkyl silane as filler; 0.022% sodium pentanesulfonate solution (adjusted to pH 3.5 with phosphoric acid)-phosphate buffer solution (6.8g of potassium dihydrogen phosphate, ml of water, the pH value was adjusted to 3.0 with phosphoric acid, and then diluted to 1000ml with water. The mobile phase was methanol-acetonitrile (26:55:23:15); The detection wavelength was 220nm. The number of theoretical plates shall not be less than 3000 calculated by ticlopidine peak.
assay
take about 50mg of this product, precision weighing, put it in 50ml measuring flask, add mobile phase to dissolve and dilute to the scale, shake, take 5ml precision, put it in 50ml measuring flask, dilute to the scale with mobile phase, shake well, as a test solution, and inject 20u1 into the liquid chromatograph with precise amount, record the chromatogram; Take the ticlopidine hydrochloride reference substance, and determine with the same method. According to the external standard method to calculate the peak area, that is.
Last Update：2022-01-01 15:35:52
5-(2-chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine - Category
Authoritative Data Verified Data
Anti-platelet aggregation drugs.
Last Update：2022-01-01 15:35:52
5-(2-chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine - Storage
Authoritative Data Verified Data
light shielding, sealed storage.
Last Update：2022-01-01 15:35:52
5-(2-chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine - Ticlopidine Hydrochloride Tablets
Authoritative Data Verified Data
This product contains ticlopidine hydrochloride (C14H14C1NS • HCl) should be 90.0% to 110.0% of the label.
trait
This product is sugar-coated tablet or film-coated tablet, white or almost White after removing the coating.
identification
- Take appropriate amount of fine powder of this product (about equivalent to ticlopidine hydrochloride lmg ), add formaldehyde sulfuric acid test solution in lml, the liquid surface is purple red.
- in the chromatogram recorded under the content determination item, the retention time of the main peak of the test solution should be consistent with the retention time of the main peak of the reference solution.
- take an appropriate amount of fine powder of this product, add water to dissolve and dilute to make a solution containing about 0.4mg of ticlopidine hydrochloride per 1 ml, filter and take the filtrate, absorption maxima were determined by UV-Vis spectrophotometry (General 0401) at wavelengths of NM and Nm.
- take an appropriate amount of the fine powder of this product, add water, shake to dissolve ticlopidine hydrochloride, filter, and the filtrate shows chloride to identify the reaction of (1) (General rule 0301).
examination
- appropriate amount of fine powder (equivalent to ticlopidine hydrochloride 30mg) under the content determination item for related substances is placed in a 100ml measuring flask, add mobile phase to dissolve ticlopidine hydrochloride and dilute to the scale, shake, filter, and take the continued filtrate as the test solution, determination of related substances of ticlopidine hydrochloride according to the method. If there are impurity peaks in the chromatogram of the test solution, the sum of each impurity peak area shall not be greater than the main peak area of the control solution (1.0%).
- the dissolution of this product, according to the dissolution and release determination method (General rule 0931 first method), with water as the dissolution medium, the speed is 100 rpm, according to the law, after 45 minutes, the solution is filtered, and the appropriate amount of the filtrate is taken in a precise amount and diluted with water to make about 0.1 mg of the solution, as a test solution; Another ticlopidine hydrochloride control, precision weighing, water dissolved and quantitative dilution to make every 1 ml containing about 0.1 mg solution, as a control solution. According to the chromatographic conditions under the content determination item, take 20 u1 of the test solution and the reference solution, respectively inject the human liquid chromatograph, record the chromatogram, the dissolution amount of each tablet was calculated by the peak area according to the external standard method. The limit is 80% of the labeled amount and shall be in accordance with the provisions.
- others shall be in accordance with the relevant provisions under the item of tablets (General rule 0101).
Content determination
take an appropriate amount of fine powder of this product (about 25mg of ticlopidine hydrochloride), put it in a 50ml measuring flask, and add an appropriate amount of mobile phase, shake to dissolve and dilute ticlopidine hydrochloride to scale, shake well, filter, Take 5ml of continued filtrate precisely, put it in a 25ml measuring flask, dilute to scale with mobile phase, shake well, as the test solution, according to the method under the determination of the content of ticlopidine hydrochloride, it is obtained.
category
Same as ticlopidine hydrochloride.
specification
(1)0.125g (2)0.25g
storage
light shielding, sealed storage.
Last Update：2022-01-01 15:35:53
5-(2-chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine - Ticlopidine Hydrochloride Capsules
Authoritative Data Verified Data
This product contains ticlopidine hydrochloride (C14H14C1NS • HCl) should be 90.0% to 110.0% of the label.
trait
The content of this product is white or white particles or powder.
identification
- appropriate amount of fine powder (about equivalent to 1 mg of ticlopidine hydrochloride) in the content measurement item was added to 1 ml of formaldehyde sulfuric acid test solution, and the liquid surface was purplish red.
- in the chromatogram recorded under the content determination item, the retention time of the main peak of the test solution should be consistent with the retention time of the main peak of the reference solution.
- take an appropriate amount of fine powder under the content determination item, add water to dissolve and dilute to make a solution containing about 0.4mg of ticlopidine hydrochloride per 1 ml, filter and take the filtrate, absorption maxima were determined by UV-Vis spectrophotometry (General 0401) at wavelengths of NM and Nm.
- the appropriate amount of fine powder under the content measurement item was taken, and ticlopidine hydrochloride was dissolved by shaking with water, filtered, and the filtrate showed the reaction of chloride identification (1) (General 0301).
examination
- appropriate amount of fine powder (equivalent to ticlopidine hydrochloride 30mg) under the content determination item for related substances is placed in a 100ml measuring flask, add mobile phase to dissolve ticlopidine hydrochloride and dilute to the scale, shake, filter, and take the continued filtrate as the test solution, determination of related substances of ticlopidine hydrochloride according to the method. If there are impurity peaks in the chromatogram of the test solution, the sum of each impurity peak area shall not be greater than the main peak area of the control solution (1.0%).
- the dissolution of this product, according to the dissolution and release determination method (General rule 0931 The first method), water 500ml (G specification) or 1000ml (G specification) as the dissolution medium, after 30 minutes, take an appropriate amount of the solution, filter it, and accurately take 10ml of the filtrate, place it in a 25ml measuring flask, dilute it to the scale with water, and shake it, as a test solution; Another ticlopidine hydrochloride reference, precision weighing, water dissolved and quantitative dilution made in each 1 ml containing about 0.1 mg solution, as a control solution. According to the chromatographic conditions under the content determination item, take 20 u1 of the test solution and the reference solution, respectively inject the human liquid chromatograph, record the chromatogram, according to the external standard method, the dissolution amount of each particle was calculated by the peak area. The limit is 85% of the labeled amount and shall be in accordance with the provisions.
- others should comply with the relevant provisions under the capsule (General 0103).
Content determination
take the contents under the difference of loading amount, mix evenly, grind finely, weigh an appropriate amount (equivalent to ticlopidine hydrochloride 25mg) accurately, and put it in a 50ml measuring flask, add appropriate amount of mobile phase, shake to dissolve ticlopidine hydrochloride and dilute to the scale, shake well, filter, Take 5ml of filtrate accurately and put it in a 25ml measuring flask, dilute with mobile phase to the scale, shake, as a test solution, according to the method under the content determination of ticlopidine hydrochloride. According to the external standard method to calculate the peak area, that is.
category
Same as ticlopidine hydrochloride.
specification
(l)0.125g ( 2 ) 0.25g
storage
light shielding, sealed storage.
Last Update：2022-01-01 15:35:54
5-(2-chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine - Reference Information
| overview | ticlopidine hydrochloride is an antiplatelet aggregation drug, the active ingredient of ticlopidine, an antithrombotic drug, used to prevent and treat circulatory disorders of the heart, brain and other arteries caused by high platelet aggregation. |
| application | ticlopidine hydrochloride is suitable for the prevention and treatment of circulatory disorders of heart, brain and other arteries caused by high platelet aggregation and adjuvant treatment of percutaneous coronary intervention. |
| pharmacological effects and mechanism of action | pharmacological studies have shown that ticlopidine can reduce platelet adhesion and improve microcirculation by blocking the receptor of fibrinogen on platelets. In vitro tests found that ticlopidine can inhibit the adhesion of platelets on the glass plate, and undoubtedly further inhibit the aggregation and release of platelets and even the formation of thrombus. The mechanism of action may be to change one, two or all of the three components of collagen and microfibrils, hemopolymerization factor VIII-related protein, and platelet membrane glycoprotein I(GIP). Therefore, ticlopidine reduces platelet adhesion, inhibits platelet aggregation, inhibits the release of active substances, enhances platelet depolymerization, and has an inhibitory effect on all stages of platelet aggregation. It is the leading broad-spectrum platelet aggregation inhibitor, and after stopping the drug, the bleeding time and other platelet function tests of most patients can return to normal within 1 week. |
| pharmacodynamic | ticlopidine is easily absorbed by oral administration, fast and complete. generally, the blood drug concentration reaches a peak after 2 hours. taking it after a meal can increase the biological effect, and taking acid making agent in advance can reduce the absorption of the drug. After absorption, it is mainly oxidized and metabolized in the liver, and the antiplatelet effect of its metabolite acetone ticlopidine is 5-10 times that of its mother. The bioavailability of oral ticlopidine is 80%-90%. Platelet aggregation can be inhibited after taking the medicine for 24-48h. The protein binding rate is about 98%, and the elimination half-life is 24-96h. It still has effect 72h after the last dose of normal medicine. The active ingredients of the 60% are converted into metabolites and excreted by feces. However, the pharmacokinetic changes of patients with liver and kidney dysfunction have not been fully studied. |
| biological activity | Ticlopidine HCl is a P2 receptor inhibitor that can inhibit ADP-induced platelet aggregation with an IC50 of about 2 μM. |
| Target | Value |
| P2 receptor | ~2 μM |
| category | toxic substances |
| toxicity classification | poisoning |
| acute toxicity | oral-rat LD50: 1780 mg/kg; Oral-mouse LD50: 600 mg/kg |
| flammability hazard characteristics | combustible; combustion produces toxic sulfur oxides, nitrogen oxides and hydrogen chloride smoke |
| storage and transportation characteristics | warehouse ventilation and low temperature drying |
| fire extinguishing agent | dry powder, foam, sand, carbon dioxide, mist water |
Last Update：2024-04-09 15:16:51
![5-(2-chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine](http://res.chembk.com/assets/str/2d/5/53/53885-35-1.png)
Supplier List
Spot supply
Product Name: Ticlopidine Hydrochloride Visit Supplier Webpage Request for quotationCAS: 53885-35-1
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
Spot supply
Product Name: Ticlopidine Hydrochloride Visit Supplier Webpage Request for quotationCAS: 53885-35-1
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
View History